Literature DB >> 23571537

In vitro activity of novel gyrase inhibitors against a highly resistant population of Pseudomonas aeruginosa.

Pamela R Tessier1, David P Nicolau.   

Abstract

The activity of five novel gyrase inhibitors was evaluated against 303 nonduplicate Pseudomonas aeruginosa strains collected from 53 North American institutions. The most active compound, GP-2, displayed MIC(50) and MIC(90) values of 1 and 2 μg/ml, respectively. Cross-resistance to other commercially available antipseudomonal compounds was not evident, as no major change was observed in the gyrase inhibitor MIC distribution when stratified by nonsusceptible phenotypes, including the fluoroquinolones and those isolates classified as multidrug resistant (MDR).

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23571537      PMCID： PMC3716190          DOI： 10.1128/AAC.01740-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.

Authors:  Kathryn J Eagye; Mary A Banevicius; David P Nicolau
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

2.  Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.

Authors:  Micheal Trzoss; Daniel C Bensen; Xiaoming Li; Zhiyong Chen; Thanh Lam; Junhu Zhang; Christopher J Creighton; Mark L Cunningham; Bryan Kwan; Mark Stidham; Kirk Nelson; Vickie Brown-Driver; Amanda Castellano; Karen J Shaw; Felice C Lightstone; Sergio E Wong; Toan B Nguyen; John Finn; Leslie W Tari
Journal:  Bioorg Med Chem Lett       Date:  2012-12-08       Impact factor: 2.823

3.  In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

Authors:  Kathryn J Eagye; Joseph L Kuti; Christina A Sutherland; Henry Christensen; David P Nicolau
Journal:  Clin Ther       Date:  2009-11       Impact factor: 3.393

4.  Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.

Authors:  Leslie W Tari; Michael Trzoss; Daniel C Bensen; Xiaoming Li; Zhiyong Chen; Thanh Lam; Junhu Zhang; Christopher J Creighton; Mark L Cunningham; Bryan Kwan; Mark Stidham; Karen J Shaw; Felice C Lightstone; Sergio E Wong; Toan B Nguyen; Jay Nix; John Finn
Journal:  Bioorg Med Chem Lett       Date:  2012-12-05       Impact factor: 2.823

5.  Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Virna J Schuck; Mary Anne Banevicius; Marie-Eve Beaudoin; Wright W Nichols; M Angela Tanudra; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

Review 6.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132
  6 in total
  1 in total

1.  Structure-based design and synthesis of antiparasitic pyrrolopyrimidines targeting pteridine reductase 1.

Authors:  Abedawn I Khalaf; Judith K Huggan; Colin J Suckling; Colin L Gibson; Kirsten Stewart; Federica Giordani; Michael P Barrett; Pui Ee Wong; Keri L Barrack; William N Hunter
Journal:  J Med Chem       Date:  2014-07-29       Impact factor: 7.446
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.